Monitor for any FDA response or new guidance on psychedelic drug regulation, which could affect Clearmind's regulatory pathway. No near-term catalyst from this filing alone.
Price Chart
Executive Summary
Clearmind Medicine submitted recommendations to the FDA in response to a public hearing on psychedelic drug therapeutic use, advocating for new regulatory pathways for non-hallucinogenic neuroplastogens. The filing is a routine regulatory engagement update with no new clinical data, financial results, or material catalysts.
Key Facts
- Clearmind submitted recommendations to the FDA under Docket No. FDA-2026-N-7542 regarding potential future therapeutic use of psychedelic drugs.
- The company highlighted its clinical trials at Yale University and Johns Hopkins University for non-hallucinogenic neuroplastogens.
- Clearmind called for new FDA guidance on self-administration, at-home therapies, streamlined regulatory pathways, and expanded clinical trial access.
- The company also requested collaborations with the VA, DoW, and HHS to pilot at-home neuroplastogen candidates for Alcohol Use Disorder.
- No financial figures, clinical data results, or regulatory decisions were announced in this filing.
Financial Impact
No financial impact disclosed; the filing is a regulatory comment submission with no quantifiable effect.
Risk Factors
- No guarantee that FDA will adopt Clearmind's recommendations or create new regulatory pathways.
- Clinical-stage biotech with no approved products; regulatory and clinical execution risks remain high.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-107425 |
| Document: ea0307943-6k_clearmind.htm | 0001213900-26-107425 |
| Document: 0001213900-26-107425-index-headers.html | 0001213900-26-107425 |
| Document: 0001213900-26-107425-index.html | 0001213900-26-107425 |
| Document: 0001213900-26-107425.txt | 0001213900-26-107425 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | — | awaiting T+60 | — | — |
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.79%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers